#Cholangiocarcinoma Market Demand
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
Tumblr Inc. is funded by 13 investors.
Text
Global Cholangiocarcinoma Market Is Estimated To Witness High Growth Owing To Rising Incidences of the Disease
The global Cholangiocarcinoma Market is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8% over the forecast period 2021-2028, as highlighted in the new report published by Coherent Market Insights. Cholangiocarcinoma, also known as bile duct cancer, is a rare and aggressive form of cancer that affects the bile ducts. The market for Cholangiocarcinoma is driven by the increasing incidences of the disease and the need for effective treatment options. Market Overview: Cholangiocarcinoma is a deadly cancer that arises from the cells lining the bile ducts, which are responsible for carrying bile from the liver to the small intestine. This cancer is difficult to diagnose in its early stages and is often detected at an advanced stage when treatment options are limited. The market for Cholangiocarcinoma is driven by the need for targeted therapies and innovative treatment approaches to improve patient outcomes. Currently, there are limited treatment options available for patients with Cholangiocarcinoma, which creates a significant unmet need in the market. Market Key Trends: One key trend in the Cholangiocarcinoma Market is the increasing focus on precision medicine and targeted therapies. Precision medicine involves tailoring treatment plans based on an individual's genetic makeup, allowing for more personalized and effective treatments. Several pharmaceutical companies are investing in research and development to identify specific genetic mutations and biomarkers associated with Cholangiocarcinoma to develop targeted therapies. For example, Incyte Corporation and QED Therapeutics are conducting clinical trials for their targeted therapy, pemigatinib, which has shown promising results in patients with locally advanced or metastatic Cholangiocarcinoma. PEST Analysis: - Political: Government initiatives and regulations play a crucial role in the development and availability of treatments for Cholangiocarcinoma. Governments are increasingly focusing on improving cancer care and funding research programs. - Economic: The economic impact of Cholangiocarcinoma is significant, as it requires long-term treatment and care. The high cost of treatment options and supportive care pose challenges for patients and healthcare systems. - Social: The increasing awareness about Cholangiocarcinoma among the general population and healthcare professionals is driving early detection and diagnosis. Support groups and patient advocacy organizations are providing support and resources to patients and their families. - Technological: Advances in diagnostic technologies, such as molecular testing and imaging techniques, are enabling early detection and accurate diagnosis of Cholangiocarcinoma. Additionally, the development of targeted therapies and immunotherapies is revolutionizing the treatment landscape for this aggressive cancer. Key Takeaways: In terms of market size, the global Cholangiocarcinoma market is expected to witness high growth, exhibiting a CAGR of 12.8% over the forecast period, due to increasing incidences of the disease. The rising prevalence of risk factors such as primary sclerosing cholangitis (PSC), hepatitis B and C infections, and exposure to certain chemicals and toxins are contributing to the growing incidence of Cholangiocarcinoma. Moreover, the lack of effective treatment options for this aggressive cancer creates opportunities for pharmaceutical companies to develop innovative therapies to improve patient outcomes. Key players operating in the global Cholangiocarcinoma market are Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc. These companies are focusing on strategic collaborations, clinical trials, and research and development activities to develop effective treatment options for Cholangiocarcinoma.
#Cholangiocarcinoma#Cholangiocarcinoma Market#Cholangiocarcinoma Market Size#Cholangiocarcinoma Market Demand#Cholangiocarcinoma Market Growth#Pharmaceutical
0 notes
Text
Radiofrequency Ablation (RFA) Devices Market to Witness 9.37% CAGR Growth Between 2024 and 2030
According to a recent comprehensive by MarkNtel Advisors Radiofrequency Ablation (RFA) Devices Market research report, the Radiofrequency Ablation (RFA) Devices market is set for significant growth, driven by factors such as market size, share, and evolving trends.
This detailed report offers crucial insights into the market, covering key aspects such as market segmentation and definitions. It outlines the main drivers of growth and provides a clear forecast of the industry’s future direction. Additionally, the study provides a thorough overview of the competitive landscape, detailing recent developments and regional distribution across major areas. An expert competitor analysis delivers an in-depth understanding of market dynamics, offering strategic recommendations for businesses and investors.
✅In case you missed it, we are currently revising our reports. Click on the below to get the latest research data with forecast for years 2025 to 2030, including market size, industry trends, and competitive analysis. It wouldn’t take long for the team to deliver the most recent version of the report.
With its robust analysis and forward-looking projections, this report is an essential resource for stakeholders aiming to leverage emerging opportunities and address potential challenges in the Radiofrequency Ablation (RFA) Devices market.
Get a Sample PDF of Report - https://www.marknteladvisors.com/query/request-sample/radiofrequency-ablation-devices-market.html
Radiofrequency Ablation (RFA) Devices Market (2024-2030): Analysis and Growth
The Global Radiofrequency Ablation (RFA) Devices Market is estimated to grow at a CAGR of around 9.37% during the forecast period, i.e., 2024-30
What are the key drivers fueling growth in the Radiofrequency Ablation (RFA) Devices market from 2024-2030?
Increasing Incidences of Gastrointestinal Diseases to Drive Market Growth – Globally, some of the important thing illnesses that RFA devices have these days include cholangiocarcinoma, esophageal squamous mobile dysplasia, and so forth. Therefore, due to their expanded prevalence, specifically throughout growing countries like Brazil, India, Mexico, etc., the demand for RFA gadgets has stepped forward. Also, the incidence of gastrointestinal infections has appreciably long gone up, and this has been fueling demand for much less invasive approaches along with RFA gadgets for functions of treatment.
Radiofrequency Ablation (RFA) Devices Market : Segmentation Analysis
-By Product Type
-Radiofrequency Generators- Market Size & Forecast 2019-2030, USD Million
-Consumables- Market Size & Forecast 2019-2030, USD Million
-Radiofrequency Electrodes- Market Size & Forecast 2019-2030, USD Million
-Radiofrequency Probes- Market Size & Forecast 2019-2030, USD Million
-Radiofrequency Catheters- Market Size & Forecast 2019-2030, USD Million
-Radiofrequency Cannulas- Market Size & Forecast 2019-2030, USD Million
-Others (RF Needles, Grounding Pads, etc.)- Market Size & Forecast 2019-2030, USD Million
-By Procedure Type
-Bipolar Radiofrequency Ablation- Market Size & Forecast 2019-2030, USD Million
-Unipolar Radiofrequency Ablation- Market Size & Forecast 2019-2030, USD Million
-Others (Pulsed RFA, Laser RFA, etc.) - Market Size & Forecast 2019-2030, USD Million
-By Application
-Cardiology- Market Size & Forecast 2019-2030, USD Million
-Oncology- Market Size & Forecast 2019-2030, USD Million
-Pain Management- Market Size & Forecast 2019-2030, USD Million
-Neurology- Market Size & Forecast 2019-2030, USD Million
-Others (Thyroid, Gynecological, etc.)- Market Size & Forecast 2019-2030, USD Million
-By End User
-Hospitals- Market Size & Forecast 2019-2030, USD Million
-Ambulatory Surgical Centers- Market Size & Forecast 2019-2030, USD Million
-Others (Specialty Clinics, Research Organizations, etc.)- Market Size & Forecast 2019-2030, USD Million
-By Region
-North America
-South America
-Europe
-The Middle East & Africa
-Asia-Pacific
Explore the Complete Analysis Report – https://www.marknteladvisors.com/research-library/radiofrequency-ablation-devices-market.html
What role do key competitors play in shaping the market, and how are they adapting to emerging trends and challenges?
Boston Scientific Corporation, Pajunk, Abbott, Medtronic, Stryker, BIOTRONIK Schweiz AG, AngioDynamics, CONMED Corporation, Lepu Medical Technology(Beijing)Co., Ltd., Arthrex, Inc., STARmed Co., Ltd., AVNS, Olympus, BVM Medical Limited (RF Medical), Johnson & Johnson Services, Inc., Others
Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.”
Key Questions Answered in the Research Report:
What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
What are the trends influencing the current scenario of the market?
What key factors would propel and impede the industry across the country?
How has the industry been evolving in terms of geography & solution adoption?
How have buying behavior, customer inclination, and expectations from product manufacturers been evolving during 2024-30?
Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?
Why MarkNtel Advisors?
MarkNtel Advisors is a leading research, consulting, & data analytics firm that provides an extensive range of strategic reports on diverse industry verticals. We deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, & individuals, among others.
Our specialization in niche industries & emerging geographies allows our clients to formulate their strategies in a much more informed way and entail parameters like Go-to-Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, & trend analysis, among others, for 15 diverse industrial verticals.
For Media Inquiries, Please Contact:
Email: [email protected]
Sales Office: 564 Prospect St, B9, New Haven, Connecticut, USA-06511
Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301
0 notes
Text
Primary Sclerosing Cholangitis Market Size, Share and Future News by 2025-2033
The Reports and Insights, a leading market research company, has recently releases report titled “Primary Sclerosing Cholangitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033.” The study provides a detailed analysis of the industry, including the global Primary Sclerosing Cholangitis Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the Primary Sclerosing Cholangitis Market?
The global primary sclerosing cholangitis market was valued at US$ 174.9 Million in 2024 and is expected to register a CAGR of 7.8% over the forecast period and reach US$ 370.8 Million in 2033.
What are Primary Sclerosing Cholangitis?
Primary sclerosing cholangitis (PSC) is a chronic liver condition characterized by ongoing inflammation and scarring of the bile ducts, leading to their narrowing, obstruction, and subsequent liver damage. Symptoms may include jaundice, itching, abdominal pain, and fatigue. PSC is often linked to an increased risk of liver cirrhosis and liver cancer. While the precise cause remains unclear, the disease is thought to involve autoimmune mechanisms and is frequently associated with inflammatory bowel diseases like ulcerative colitis. Treatment aims to alleviate symptoms, slow disease progression, and manage complications, with liver transplantation being a potential option for advanced stages.
Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2389
What are the growth prospects and trends in the Primary Sclerosing Cholangitis industry?
The primary sclerosing cholangitis (PSC) market growth is driven by various factors and trends. The market for primary sclerosing cholangitis (PSC) is expanding due to heightened awareness of the disease, improvements in diagnostic methods, and advancements in treatment options. Increasing recognition of PSC, particularly its links to inflammatory bowel diseases, along with the growing incidence of liver complications, is boosting demand for effective therapies. Key players in the market include pharmaceutical and biotechnology companies focusing on new drug developments and clinical trials. The market is also driven by the need for improved symptom management and potential curative approaches, such as liver transplantation. Despite challenges like high treatment costs and limited available therapies, ongoing research and innovation are contributing to the market's growth. Hence, all these factors contribute to primary sclerosing cholangitis (PSC) market growth.
What is included in market segmentation?
The report has segmented the market into the following categories:
By Type
Classic PSC
Variant PSC
PSC Associated with Autoimmune Hepatitis
PSC with Cholangiocarcinoma
By Treatment Type
Ursodeoxycholic Acid
Obeticholic Acid
Methotrexate
Corticosteroids
Others
By Route of Administration
Oral
Parental
Others
By End-User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
United States
Canada
Europe
Germany
United Kingdom
France
Italy
Spain
Russia
Poland
Benelux
Nordic
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
ASEAN
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
Saudi Arabia
South Africa
United Arab Emirates
Israel
Rest of MEA
Who are the key players operating in the industry?
The report covers the major market players including:
Acorda Therapeutics, Inc.
Gilead Sciences, Inc.
NGM Biopharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
Falk Pharma GmbH
Allergan Plc.
Shire Plc.
Durect Corporation
Conatus Pharmaceuticals, Inc.
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceutical Ltd.
Cymabay Therapeutics
Pliant Therapeutics
Immunic AG
View Full Report: https://www.reportsandinsights.com/report/Primary Sclerosing Cholangitis-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: [email protected] Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1
#Primary Sclerosing Cholangitis Market share#Primary Sclerosing Cholangitis Market size#Primary Sclerosing Cholangitis Market trends
0 notes
Text
Veterinary Services Strategies In The Global Market: Key Insights From The 2025 Report
The global Pancreatic And Biliary Stents Market was valued at USD 354.2 million in 2023 and is projected to reach USD 511.47 million by 2031, growing at a compound annual growth rate (CAGR) of 4.7% over the forecast period of 2024-2031. This growth is driven by the increasing prevalence of pancreatic and biliary diseases, advancements in stent technology, and the growing number of minimally invasive procedures globally.
Get Free Sample Report on Pancreatic and Biliary Stents Market
Pancreatic and biliary stents are medical devices that are used to treat various conditions of the pancreas and bile ducts, including chronic pancreatitis, bile duct obstruction, pancreatic cancer, and gallstones. These stents are inserted into the ducts to help maintain their patency, ensuring the normal flow of bile or pancreatic fluids. The increasing incidence of gastrointestinal disorders, such as pancreatitis and bile duct blockages, has significantly contributed to the demand for these devices.
Key Drivers of Market Growth
Increasing Prevalence of Pancreatic and Biliary Disorders: The global rise in pancreatic and biliary diseases, including conditions such as pancreatitis, cholangiocarcinoma (bile duct cancer), and pancreatic cancer, is one of the primary factors contributing to the growth of the pancreatic and biliary stents market. According to the World Health Organization (WHO), pancreatic cancer is one of the leading causes of cancer-related deaths worldwide. As these diseases continue to affect an increasing number of people, the demand for stents, particularly in the management of these conditions, is expected to rise significantly.
Rising Adoption of Minimally Invasive Procedures: Minimally invasive procedures, including the use of endoscopic techniques to insert pancreatic and biliary stents, are increasingly preferred due to their lower risks, shorter recovery times, and reduced discomfort for patients. The growing trend of performing complex gastrointestinal procedures with minimal incision and reduced risk of complications is driving the demand for pancreatic and biliary stents. These procedures help to address conditions such as obstructed bile ducts, improving patients' quality of life and reducing the need for traditional surgery.
Technological Advancements in Stent Designs: The development of advanced stent technologies, including drug-eluting stents (DES) and biodegradable stents, is another key factor contributing to the market's growth. Drug-eluting stents, which release medication over time to prevent stent occlusion and restenosis, are increasingly being used to improve treatment outcomes. Biodegradable stents, which dissolve naturally over time, are expected to gain popularity due to their ability to reduce the need for removal procedures. These advancements are expected to boost the effectiveness of treatments and improve patient outcomes, further driving the growth of the pancreatic and biliary stents market.
Growing Demand for Advanced Medical Treatments: As healthcare systems across the globe continue to improve, the demand for advanced medical treatments is on the rise. This includes the increased use of stents for the management of complex pancreatic and biliary conditions. Rising healthcare expenditures and the increasing availability of healthcare services in emerging economies are expected to drive the adoption of pancreatic and biliary stents in these regions, further expanding the market.
Aging Population: The aging global population is another important driver for the growth of the pancreatic and biliary stents market. Older individuals are more susceptible to pancreatic and biliary diseases due to factors such as weakened immune systems, chronic conditions, and lifestyle factors. As the population of elderly individuals continues to rise, the demand for medical devices like pancreatic and biliary stents to manage these conditions is expected to increase.
Improved Diagnosis and Awareness: As awareness of pancreatic and biliary diseases grows, more people are seeking medical attention and receiving early diagnoses. Improvements in diagnostic imaging and technologies, such as endoscopic retrograde cholangiopancreatography (ERCP), have enabled better detection of blockages, stenosis, and other conditions affecting the bile ducts and pancreas. This early detection allows for timely intervention and the increased use of stents to treat these conditions.
KEY MARKET SEGMENTATION
By Product Type
Metal Stents
Plastic Stents
By Applications
Bilio-pancreatic leakages
Pancreatic Cancer
Benign Biliary strictures
Others
By End Users
Hospitals
Ambulatory Surgical Centers
Speciality Clinics
Others
Make Enquiry about Pancreatic and Biliary Stents Market
Competitive Landscape
The pancreatic and biliary stents market is competitive, with several key players leading the industry. Prominent companies include Boston Scientific Corporation, Cook Medical, Medtronic, Abbott Laboratories, and Terumo Corporation. These companies are focused on product innovation, expanding their market presence, and forming strategic partnerships to maintain a competitive edge.
Boston Scientific Corporation: Boston Scientific offers a range of advanced pancreatic and biliary stents, including self-expanding metal stents and plastic stents, and is a leader in the market due to its continuous innovation and product development.
Cook Medical: Cook Medical is another major player in the pancreatic and biliary stents market, known for its high-quality stent offerings and its commitment to advancing minimally invasive treatments.
Medtronic: Medtronic is a leading global healthcare company that provides a wide range of stents for various applications, including pancreatic and biliary treatments. The company's strong presence in the global medical device market gives it a competitive edge.
Conclusion
The pancreatic and biliary stents market is expected to experience significant growth, driven by the increasing prevalence of pancreatic and biliary diseases, the growing demand for minimally invasive treatments, and advancements in stent technology. With a projected market value of USD 511.47 million by 2031, the market is set to benefit from innovations such as biodegradable stents, drug-eluting stents, and improvements in stent design. As the demand for advanced gastrointestinal treatments continues to rise, pancreatic and biliary stents will play a critical role in managing these complex conditions, improving patient outcomes, and contributing to the overall growth of the healthcare industry.
About US:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave - Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
#Pancreatic and Biliary Stents Market#Pancreatic and Biliary Stents Market Size#Pancreatic and Biliary Stents Market Report#Pancreatic and Biliary Stents Market Trend#Pancreatic and Biliary Stents Market Share#Pancreatic and Biliary Stents Market Growth
0 notes
Text
The Cholangiocarcinoma Market is Estimated to Witness High Growth Owing to Opportunity to Expand Treatment Options
Cholangiocarcinoma also known as bile duct cancer is a type of cancer that forms in the bile ducts. The bile ducts are thin tubes that connect the liver and gallbladder to the small intestine. They carry a fluid called bile that helps with digestion. Symptoms of cholangiocarcinoma include weight loss, abdominal pain, jaundice, and itching. Treatment options for cholangiocarcinoma include surgery, radiation therapy, chemotherapy, radiofrequency ablation and liver transplantation. The global cholangiocarcinoma market is estimated to be valued at US$ 7,275.7 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The opportunity to expand treatment options presents a high growth opportunity for the cholangiocarcinoma market. Currently, surgery offers the only potential cure but most patients are not eligible for surgery due to advanced stage at diagnosis. Thus, there is a need for new targeted drugs and immunotherapies to treat cholangiocarcinoma. Many novel drugs and drug combinations are being evaluated in clinical trials which have shown promising results in improving patient outcomes. The successful development of effective targeted therapies and immunotherapies will drive the market growth by providing new treatment alternatives and improving survival rates of cholangiocarcinoma patients. Porter's Analysis: Threat of new entrants: Low barriers to entry as the treatment landscape is evolving, however developing specialized products requires significant investment in R&D. Bargaining power of buyers: Buyers have moderate bargaining power as there are several treatment options available. However, demand is inelastic as the disease has no cure. Bargaining power of suppliers: Key suppliers have significant bargaining power as they provide specialized products and services required for treatment with limited substitutes. Threat of new substitutes: Threat is low as no cure currently exists and developing new treatment options requires extensive research. Competitive rivalry: High as key players compete on innovation to develop new treatment methods and devices. SWOT Analysis: Strengths: Growing awareness, research funding and clinical trials for newer treatment approaches. Established regional market leaders have significantresources for R&D. Weaknesses: Low disease awareness. Diagnosis challenges due to non-specific symptoms. High costs associated with treatment and surgery. Opportunities: Expanding patient population with aging demographics. Developing economies present untapped market potential. Personalized medicine and Combination therapy options offer growthscope. Threats: Stringent regulatory norms. Reimbursement uncertainties impact product uptake. Alternative treatment strategies like liver transplantation. Key Takeaways: The global cholangiocarcinoma market is expected to witness high growth over the forecast period of 2023 to 2030. The market size for 2024 is estimated at US$ 7,275.7 Mn registering a CAGR of 7.6% over the forecast period. Regional analysis: North America holds a dominant share due to advanced healthcare systems and patient affordability for high-cost treatments in the US. Asia Pacific continues to be the fastest growing regional market with rising disease incidence in China and Japan coupled with improving access and infrastructure. Key players: Key players operating in the cholangiocarcinoma market are Johnson & Johnson Services, Inc., Cooper Companies Inc., Lifecell Corporation (Allergan Plc), W. L. Gore & Associates, Inc., Maquet Holding B.V. & Co. KG, Becton, Dickinson and Company, Medtronic Plc, Cook Medical Inc., Baxter International Inc., and B. Braun Melsungen AG.
0 notes
Text
Massive Growth In Bile Duct Cancer Treatment Market Trends By Countries, Type And Application, Top Manufacturers Pfizer, Inc., F. Hoffman-La Roche AG, Bristol-Myers Squibb Company and more..
Cholangiocarcinoma, also known as bile duct cancer, is spreading widely in Southeast Asia, particularly in the Northeast region of Thailand. High consumption of raw fish in the Asia-Pacific (APAC) region is driving the incidence of liver fluke infections, thereby stimulating the occurrence of bile duct cancer.
Increased industrialization is also attributing to the growth in the APAC bile duct cancer treatment market as exposure to harmful printing chemicals is high among industrial workers in countries such as China, Japan and India.
Strategizing The Moves For The Next Decade? See Through Sample Of Bile Duct Cancer Treatment Market Report! https://www.persistencemarketresearch.com/samples/10094
Company Profiles
Pfizer, Inc.
F. Hoffman-La Roche AG
Bristol-Myers Squibb Company
Teva Pharmaceuticals Industries Ltd.
Eli Lilly and Company
Novartis AG
Sanofi
Fresenius Kabi AG
Mylan N.V.
Kyowa Hakko Kirin Co Ltd.
Intercept Pharmaceuticals, Inc.
Accord Healthcare Inc.
Delcath Systems Inc.
Celgene Corporation
Johnson & Johnson
Starting With The New Decade On A Diligent Note In The Bile Duct Cancer Treatment Market? https://www.persistencemarketresearch.com/methodology/10094
Persistence Market Research’s new study on the global bile duct cancer treatment market reveals that by the end of 2025, APAC region will procure a global revenue share of over 45%.
In 2017, the global market for bile duct cancer treatments is anticipated to bring in revenues worth a little over US$ 168 Mn. Apart from rising incidence of bile duct cancer across the APAC and Middle East & Africa region, increasing healthcare spending is also expected to drive the demand for bile duct cancer treatments.
Towards the end of 2025, the global bile duct cancer treatment market is projected to soar at a robust CAGR of 8%, raking in revenues worth US$ 312.3 Mn.
Bile Duct Cancer Treatment – Key Challenges
The study has observed following factors as key hurdles hindering the overall expansion of global Cholangiocarcinoma treatment market:
high costs of cancer treatment in the US
lack of awareness on causes of Cholangiocarcinoma in developing regions
regulatory agencies rebuffing approval of expensive drugs
unavailability of effective cancer care in APAC region
poor diagnosis rate and absence of clinical data
The study also reveals that ongoing trials for development of drugs on bile duct cancer treatment are creating newer pathways for improving the efficiency of treatment. Companies are exploring the clinical benefits of fusing new chemical entities in existing drugs on treatment of bile duct cancer.
How About Obtaining Insights About The Region To Enter Concerning The Bile Duct Cancer Treatment Market? Press The “Purchase Now” Button To Have Our Bile Duct Cancer Treatment Market Report! https://www.persistencemarketresearch.com/checkout/10094
The key players in global bile duct cancer treatment market are also seeking regulatory approval of combination therapies for treatment of Cholangiocarcinoma.
Key Excerpts from the Study
Treatment of bile duct cancer is presently achieved through combination therapies associated with chemotherapy. The study anticipates that by the end of forecast period, close to 70% of global bile duct cancer treatment revenues will be accounted by the Gemicitabine Combination Therapy.
In 2017 and beyond, more than 85% of global market value will be attributed by extrahepatic Cholangiocarcinoma as a disease indicator.
The study also observes hospital pharmacies as largest distribution channel for bile duct cancer drugs, revenues from which are expected to reach nearly US$ 250 Mn by 2025-end.
The global market for Cholangiocarcinoma treatment is also witnessing dominance from external beam radiation therapy as these services are pegged to procure more than half of market’s value through 2025.
About Us :-
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.
Contact us:
Persistence Market Research Address – 305 Broadway, 7th FloorNew York City, NY 10007 United States U.S. Ph. – +1-646-568-7751 USA-Canada Toll-free – +1 800-961-0353 Sales – [email protected] Website – https://www.persistencemarketresearch.com
0 notes
Text
Research Nester published a report titled “Liver Cancer Therapeutics Market: Global Demand Analysis & Opportunity Outlook 2031” which delivers detailed overview of liver cancer therapeutics in terms of market segmentation by type, therapy, and by region.
Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
The global of liver cancer therapeutics market is estimated to garner significant revenue by growing at a CAGR of 20.2% over the forecast period, i.e., 2022 – 2031. The growth of the market can be attributed to growing prevalence of liver cancer, and rise in incidence of hepatitis B infection in developing countries. According to the World Health Organisation, liver cancer was ranked third in the most common causes of cancer death in the world in 2020, causing nearly 830,000 deaths, while in 2019, hepatitis B resulted in an estimated 820,000 deaths globally. The market is segmented by type into hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and others, out of which, the hepatocellular carcinoma segment is anticipated to hold the largest share in the global liver cancer therapeutics market over the forecast period. In 2018, there were an estimated number of 661,000 cases of hepatocellular carcinoma recorded worldwide, that contributed 80% of the world total liver cancer burden.
Geographically, the global liver cancer therapeutics market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region, out of which, North America is anticipated to hold the largest market share owing to high awareness about liver cancer, presence of well-established healthcare infrastructure, and easy drug availability. Additionally, Asia-Pacific region is estimated to witness growth at the highest rate during the forecast period.
In Q4 2021, USA current-account deficit widened stood at $224.8 billion. However, in Q1 22, CAD rose by 29.6%, reached to $291.4 billion, adding $66.6 billion to the gap. Export of good and services increased by $25.7 billion to reach $1.03 trillion in the first quarter of 2022. However, goods and services deficit was $79.6 billion in June, down $5.3 billion from $84.9 billion in May, revised- reflecting some sight of relief. On the other hand, annual inflation rate in the country hit 8.5%. Energy CPI surged by 32.9% in July 2022, inflating the cost of logistic and some signs to disrupt supply chain whilst electricity cost upsurged by 15.2%, highest since Feb 2006. Apart from that, In July 2022, existing US home sales declined 5.9% to 4.81 million (seasonally adjusted annual rate), the lowest since May of 2020 and below market expectations of 4.89 million. As mortgage rate touches to peak 6%, sales for houses declined for a sixth consecutive month. Global energy crises to remain at focal point, pushing consumers to spend less on the products and services and save more.
On the other hand, the worst is expected to be seen in the European countries especially during 2022 winters. The energy and gas crises has already started grappling the region where in many Western European countries including Germany is looking for coal fired solutions to tackle the gas supply shortage, created by Russian-Ukraine conflict.
Amidst global concerns, market players have started looking for safe investments by holding on to the new technology and product launches. Factors like currency translation, disruption in global supply chain, Anti-China sentiments brewing across the globe, slowdown in Chinese economy, inflated products prices, USD getting stronger every week, decreasing purchasing power and strict measures taken by central banks/institutions across the world to ensure less spending and more saving, could hit the demand for the product and service badly in near future.
Healthcare Companies and Private Service Providers to have a minimal damage Caused by Inflation:
As US govt. remains committed to quality by spending more in the Medicaid and Medicare programs, incentives by govt. to medical devices, pharma companies and biotech to benefit the market players in short and long term goals. In 2021, U.S. spent $12,318/person on healthcare- highest amongst all OECD countries followed by Germany at $7,383. The federal government commitment towards healthcare systems to enable market players expanding their revenues and mitigating the risk posed by the inflation.
Download Sample of This Strategic Report @ https://www.researchnester.com/sample-request-4114
The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.
Growing Prevalence of Liver Cancer and Advancement in Cancer Therapeutics with Emergence of Targeted Therapies to Boost Market Growth
Liver cancer is the sixth most common type of cancer in the world and recorded a number of 905,677 cases in 2020, as per statistics by the International Agency for Research on Cancer (IARC). Growing prevalence of liver cancer over high alcohol consumption, non-alcoholic fatty liver disease, is one of the key factors driving the growth of the market. Moreover, targeted therapy is considered a breakthrough in the field of medical oncology, which determined an improvement in the effectiveness of cancer treatments. Increasing R&D activities and advancement in targeted cancer therapies are also expected to foster the growth of the global liver cancer therapeutics market.
Curious about this latest version of report? Obtain Report Details @ https://www.researchnester.com/reports/liver-cancer-therapeutics-market/4114
However, high cost and side effects related to certain liver cancer therapies, and limitations in treatment options with several therapies in clinical trial stage are expected to restrain the growth of global liver cancer therapeutics market over the forecast period.
This report also provides the existing competitive scenario of some of the key players of the global liver cancer therapeutics market which includes company profiling of Bristol-Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., Merck Sharp & Dohme Corp. (Merck & Co., Inc.), Bayer AG, Zymeworks Inc., F. Hoffmann-La Roche Ltd., Celsion Corporation, Eli Lilly and Company, AstraZeneca, among others. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global liver cancer therapeutics market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Ask Industry Experts about this Report @ https://www.researchnester.com/sample-request-4114
0 notes
Link
The“Bile Duct Cancer Market ”reportfocuses on the market status, future forecast, growth opportunities, market trends and leading players.
0 notes
Text
Cholangiocarcinoma Market To Surpass US$ 429.6 Million By 2028
Cholangiocarcinoma is a type of cancer that forms in the slender tubes (bile ducts) that carry the digestive fluid bile. The specific reason for the cause of cholangiocarcinoma is not known as of yet. The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural) and may sometimes affect gall bladder as well. The significant symptoms of cholangiocarcinoma includes jaundice, weight reduction, loss of hunger, blood in stool and urine, stomach pain, fever, and itching.
The global cholangiocarcinoma market is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8 % during the forecast period (2021-2028).
Increasing prevalence of cholangiocarcinoma is expected to drive the market growth during the forecast period.
Increasing prevalence of cholangiocarcinoma is expected to drive the global cholangiocarcinoma market growth over the forecast period. For instance, according to American Cancer Society’s 2018 report, around 8,000 people in the U.S. are diagnosed with cholangiocarcinoma to each year. This includes both intrahepatic (inside the liver) and extrahepatic (outside the liver) bile duct cancers.
Request Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/4435
Key players operating in the global cholangiocarcinoma market are focusing on adoption of inorganic growth strategies such as acquisition which are expected to drive the market growth during the forecast period.
key companies are focusing on inorganic strategies such as acquisition in order to strengthen their products presence and this is expected to create a conductive environment for growth of the Cholangiocarcinoma market. For instance, in January 2021, Servier, a global pharmaceutical company, announced the acquisition of Agios Pharmaceuticals company’s commercial, clinical, and research-stage oncology portfolio which includes Tibsovo (ivosidenib tablets) for treatment of Cholangiocarcinoma and others.
Global Cholangiocarcinoma Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread over 100 countries across the globe and the World Health Organization had declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 143 million infected individuals worldwide as of April 21st 2021.
COVID-19 affects the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs. For instance, In April 2020, Chinese suppliers stopped supplies to India due to non-availability of labour, containers are piling up and all space is occupied. The incoming vessels will not be able to offload the containers and may bypass that result in the shortage of medicines in India.
Furthermore, players operating in the global cholangiocarcinoma market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges includes supply of raw materials (due to irregularities in transportation), which are required for manufacturing drug formulations. Moreover, distributors are experiencing irregular demand for products from the retailers due to an increase in the number of patients suffering from COVID-19 and other life threatening disorders.
Global Cholangiocarcinoma Market: Restraint
The major factors that hinder growth of the global cholangiocarcinoma market includes high cost of cholangiocarcinoma and cancer treatments and the time-consuming approach for approving new drugs.
Key Players
Major players operating in the global cholangiocarcinoma market are Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc.
Buy Now this Research Report: https://www.coherentmarketinsights.com/insight/buy-now/4435
About US:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: [email protected]
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
0 notes
Text
Expected Growth, Market Analysis, And Regional Analysis Of Cholangiocarcinoma Market
Cholangiocarcinoma is cancer that develops in the bile ducts, which transport the digesting fluid bile. Cholangiocarcinoma is caused by a variety of factors that are unknown at this time. The malignant tumor can grow from any part of the bile duct, including the terminal ductules (Canals of Hering) to the ampulla of Vater and the peribiliary glands (intramural and intramural) extramural), and it can occasionally damage the gallbladder.
In 2021, the global Cholangiocarcinoma Market is predicted to be worth US$ 185.4 million, growing at a CAGR of 12.8 percent over the forecast period (2021-2028). Over the forecast period, the worldwide cholangiocarcinoma market is expected to rise due to rising cholangiocarcinoma prevalence. COVID-19 has three primary effects on the economy: it directly affects production and demand, disrupts distribution routes, and has a financial impact on businesses and financial markets. In addition, several countries, including China, India, Saudi Arabia, the United Arab Emirates, Egypt, and others, are experiencing difficulties transporting pharmaceuticals due to statewide lockdowns.
Read More: https://coherentmarketblogs.blogspot.com/2021/08/the-cholangiocarcinoma-market-is.html
0 notes
Text
Primary Sclerosing Cholangitis Market Size, Share and Future News by 2025-2033
The Reports and Insights, a leading market research company, has recently releases report titled “Primary Sclerosing Cholangitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033.” The study provides a detailed analysis of the industry, including the global Primary Sclerosing Cholangitis Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the Primary Sclerosing Cholangitis Market?
The global primary sclerosing cholangitis market was valued at US$ 174.9 Million in 2024 and is expected to register a CAGR of 7.8% over the forecast period and reach US$ 370.8 Million in 2033.
What are Primary Sclerosing Cholangitis?
Primary sclerosing cholangitis (PSC) is a chronic liver condition characterized by ongoing inflammation and scarring of the bile ducts, leading to their narrowing, obstruction, and subsequent liver damage. Symptoms may include jaundice, itching, abdominal pain, and fatigue. PSC is often linked to an increased risk of liver cirrhosis and liver cancer. While the precise cause remains unclear, the disease is thought to involve autoimmune mechanisms and is frequently associated with inflammatory bowel diseases like ulcerative colitis. Treatment aims to alleviate symptoms, slow disease progression, and manage complications, with liver transplantation being a potential option for advanced stages.
Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2389
What are the growth prospects and trends in the Primary Sclerosing Cholangitis industry?
The primary sclerosing cholangitis (PSC) market growth is driven by various factors and trends. The market for primary sclerosing cholangitis (PSC) is expanding due to heightened awareness of the disease, improvements in diagnostic methods, and advancements in treatment options. Increasing recognition of PSC, particularly its links to inflammatory bowel diseases, along with the growing incidence of liver complications, is boosting demand for effective therapies. Key players in the market include pharmaceutical and biotechnology companies focusing on new drug developments and clinical trials. The market is also driven by the need for improved symptom management and potential curative approaches, such as liver transplantation. Despite challenges like high treatment costs and limited available therapies, ongoing research and innovation are contributing to the market's growth. Hence, all these factors contribute to primary sclerosing cholangitis (PSC) market growth.
What is included in market segmentation?
The report has segmented the market into the following categories:
By Type
Classic PSC
Variant PSC
PSC Associated with Autoimmune Hepatitis
PSC with Cholangiocarcinoma
By Treatment Type
Ursodeoxycholic Acid
Obeticholic Acid
Methotrexate
Corticosteroids
Others
By Route of Administration
Oral
Parental
Others
By End-User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
United States
Canada
Europe
Germany
United Kingdom
France
Italy
Spain
Russia
Poland
Benelux
Nordic
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
ASEAN
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
Saudi Arabia
South Africa
United Arab Emirates
Israel
Rest of MEA
Who are the key players operating in the industry?
The report covers the major market players including:
Acorda Therapeutics, Inc.
Gilead Sciences, Inc.
NGM Biopharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
Falk Pharma GmbH
Allergan Plc.
Shire Plc.
Durect Corporation
Conatus Pharmaceuticals, Inc.
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceutical Ltd.
Cymabay Therapeutics
Pliant Therapeutics
Immunic AG
View Full Report: https://www.reportsandinsights.com/report/Primary Sclerosing Cholangitis-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: [email protected] Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1
#Primary Sclerosing Cholangitis Market share#Primary Sclerosing Cholangitis Market size#Primary Sclerosing Cholangitis Market trends
0 notes
Text
Liver Cancer Therapeutics Market Global Recent Trend, Industry Size, Share, Merger
Liver cancer is a type of malignant hepatic tumor in or on the liver, which may cause due to excessive alcohol intake, diabetes, certain inherited liver diseases, and hepatitis. Symptoms of this cancer appears only when it is in the advanced stage. The most common type of liver cancer is hepatocellular carcinoma, which begins in the main type of liver cell. Other types of liver cancer such as hepatoblastoma and intrahepatic cholangiocarcinoma are less common. Incidence rate of liver cancer is high in the U.S., owing to prevalence of cirrhosis caused by nonalcoholic fatty liver disease and chronic hepatitis C. According to American Cancer Society 2017, Liver cancer is the 10th most common cancer and fifth most common cause of death among men in the U.S. Also, it is the eighth most common cause of death among women. Colorectal cancer is expected to be one of the precursor for liver cancer. According to International Scholarly Research Network, a clinical study on Percutaneous Cryoablation of Metastatic Lesions from Colorectal Cancer in 2012: Efficacy and Feasibility with Survival and Cost-Effectiveness Observations, around 50% of the patient suffering from colorectal cancer develop liver cancer.
Request for Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/1591
Liver cancer therapeutics Market – Driver
Increasing research to identify the causes of liver cancer is expected to boost growth of the liver cancer therapeutics market during the forecast period. For instance, in November, 2014, researchers at the San Diego School of Medicine and University of California found that long-term exposure to triclosan, a common ingredient in detergents and soaps, causes liver fibrosis and cancer in laboratory mice. However, triclosan has not been proven to cause liver cancer in human and it is currently under scrutiny by the Food and Drug Administration (FDA) to determine whether it has negative health impacts.
Moreover, increasing prevalence of liver cancer in various regions is expected to drive growth of the market. For instance, according to cancer research organization of UK, around 5,736 new cases of liver cancer were reported in UK in 2015. Furthermore, according to cancer organization, around 40,710 new cases of liver cancer was diagnosed in the U.S. during 2017, three of which will be hepatocellular carcinoma (HCC).
Organic and inorganic strategies by market players such as merger, collaboration, acquisition, and research and development for developing new therapies for liver cancer is expected to boost growth of the market. For instance, in 2013, Roche and Inovio Pharmaceuticals, Inc. entered into license agreement to research, develop and commercialize Inovio’s highly-optimized, multi-antigen DNA immunotherapies targeting hepatitis B and prostate cancer. It has also been shown that liver cancer risk increases substantially with the increase in Body Mass Index (BMI) of an individual. More than half of the adult population in the U.S. is overweight, which is propelling demand for therapeutic drugs of liver cancer, which in turn is creating opportunities for manufacturers.
Liver cancer therapeutics Market – Restrain
Stringent regulatory approvals to ensure the safety of drugs and cost of these drugs may hamper the growth of the liver cancer therapeutics market during the forecast period. For instance, in March 2017, ArQule, Inc’s product- tivantinib did not clear phase 3 clinical trial for hepatocellular carcinoma (HCC) in japan, as it did not meet its primary endpoint of progression free survival (PFS)
Liver cancer therapeutics Market - Regional Analysis
Geographically, global liver cancer therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position over the forecast period, owing to increasing funding for research and development activities by government. American Liver Foundation is an organization that promote education, support and research for the prevention, treatment, and cure of liver disease and since 1979, this organization has provided more than US$ 26 million in research funding. Furthermore, liver cancer is more common in economies of Sub-Saharan Africa and Southeast Asia as compared to the U.S. According to GLOBOCAN, in 2012, around 83% (50% in China alone) of the estimated 782,000 new cancer cases were reported worldwide. Moreover, in Sub Saharan African countries, the risk of developing cancer and death from the same is high, owing to the late stage diagnosis and lack of treatment, which is driving growth of the liver cancer therapeutics market.
To Get Instant Access, Purchase Report Here @ https://www.coherentmarketinsights.com/insight/buy-now/1591
Liver cancer therapeutics Market – Competitor
The market players operating in liver cancer therapeutics market include Bayer AG, Bristol-Myers Squibb Company, Onyx Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., Jennerex Biotherapeutics Inc., and Celsion Corp.
Liver cancer therapeutics Market – Taxonomy
By Drug Class
Targeted Therapy
Sorafenib (Nexavar)
Regorafenib (Stivarga)
Immunotherapy
Nivolumab (Opdivo)
Chemotherapy
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: [email protected]
0 notes
Text
Global Liver Cancer Treatment Market Statistics, Development and Growth 2018-2023
Summary - A new market study, titled “Global Liver Cancer Treatment Market Research and Forecast, 2018-2023” has been featured on Wise Guy Reports.
Liver cancer, also referred to as hepatic cancer is a disease that destructs normal cells in the liver and is caused due to hepatitis C and hepatitis B or alcohol consumption. Malignant or cancerous cells that develop in the normal cells of the liver are called hepatocellular carcinoma and the one that arises in the ducts of the liver is called cholangiocarcinoma. The increasing prevalence of liver cancer across the globe and the approval of multiple liver cancer drugs are estimated to be the major factors that are driving the growth of the market. In addition, supporting government initiatives, drug development with regards to cancer and increasing health expenditure is also estimated to be the major factors that are driving the growth of the market.
ALSO READ: https://icrowdnewswire.com/2019/10/17/liver-cancer-treatment-market-major-manufacturers-trends-demand-share-analysis-to-2023/
Over the past few years, the increased prevalence of liver cancer has been witnessed. According to the American Cancer Society, about 42,220 new cases, 30,610 in men and 11,610 in women were diagnosed in 2018 in the US. It was estimated that about 30,200 people, nearly 20,540 men, and 9,660 women will die due to liver cancer in 2018. Since 1980, liver cancer incidence has more than tripled, however, the rates in young adults have begun to decline. The prevalence of liver cancer is seen more often in men than in women. Due to the increasing prevalence of liver cancer, the demand for treatment of liver cancer will increases. As a result, the global liver cancer treatment market is expected to witness growth in the near future.
However, there are certain factors that are hampering the growth of the market. The complex clinical trials process and high treatment costs are estimated to be the major constraints in the growth of the market. Besides these restraints, growing health awareness and new research and development are estimated to develop myriad growth opportunities for the growth of the market in the near future.
The global liver cancer treatment market is further studied on the basis of the geographical regions that are contributing significantly towards the growth of the market. North America region is estimated to account for a major share in the global liver cancer treatment market owing to the increasing prevalence of liver cancer due to risk factors such as Hepatitis C virus infection and alcoholic liver disease in the region. Additionally, high adoption of innovative technology, established infrastructure for research and development and presence of key pharmaceutical companies are the major factors for growth of liver cancer market in the region. Asia-Pacific is estimated to be the fastest growing market during the forecast period. The growth is observed in the region owing to the growing aged population and increasing health expenditure in the emerging economies such as India and China.
Key players of the global liver cancer treatment market are market are 4SC AG, Alnylam Pharmaceuticals, Inc., ArQule Inc., Aveo Pharmaceuticals, Inc., Bayer AG, Bristol-Myers Squibb Co., and so on. In order to stay competitive in the market, these key players adopt strategies such as product launch, merger & acquisitions, FDA approval, geographical expansion and so forth.
Research methodology
The market study of the global liver cancer treatment market is incorporated by extensive primary and secondary research conducted by a research team at OMR. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The OMR team collects facts and data related to the market from different geographies to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. The numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analysts to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts to get first-hand information. Primary research brings authenticity to our reports.
Secondary sources include
• Financial reports of companies involved in the market
• Whitepapers, research-papers and news blogs
• Company websites and their product catalog
The report is intended for healthcare providers, research laboratories and government organization for overall market analysis and competitive analysis. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.
The report covers
• Comprehensive research methodology of the global liver cancer treatment market.
• In-depth analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the global liver cancer treatment market.
• Insights about market determinants which are stimulating the global liver cancer treatment market.
• Detailed and extensive market segments with regional distribution of researched revenues.
• Extensive profiles and recent developments of market players.
Companies Mentioned
1. 4SC AG
2. Alnylam Pharmaceuticals, Inc.
3. ArQule, Inc.
4. Aveo Pharmaceuticals, Inc.
5. Bayer AG
6. Becton and Dickinson, Co.
7. Bristol-Myers Squibb, Co.
8. Celsion Corp.
9. Dicerna Pharmaceuticals, Inc.
10. Eli Lilly and Co.
11. Exelixis, Inc.
12. F. Hoffmann-La Roche, Ltd.
13. FibroGen, Inc.
14. General Electric Co.
15. Merck KGaA
16. Novartis International AG
17. Nymox Pharmaceutical Corp.
18. Pfizer, Inc.
19. SMC Laboratories, Inc.
20. Thermo Fisher Scientific, Inc.
FOR MORE DETAILS: https://www.wiseguyreports.com/reports/3739570-global-liver-cancer-treatment-market-research-and-forecast-2018-2023
About Us: Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Contact Us:
NORAH TRENT
Ph: +162-825-80070 (US)
Ph: +44 203 500 2763 (UK)
0 notes
Text
Global Bile Duct Cancer Treatment Market Forecast From 2022
Cholangiocarcinoma, also known as bile duct cancer, is spreading widely in Southeast Asia, particularly in the Northeast region of Thailand. High consumption of raw fish in the Asia-Pacific (APAC) region is driving the incidence of liver fluke infections, thereby stimulating the occurrence of bile duct cancer.
Increased industrialization is also attributing to the growth in the APAC bile duct cancer treatment market as exposure to harmful printing chemicals is high among industrial workers in countries such as China, Japan and India.
Strategizing The Moves For The Next Decade? See Through Sample Of Bile Duct Cancer Treatment Market Report! https://www.persistencemarketresearch.com/samples/10094
Company Profiles
Pfizer, Inc.
F. Hoffman-La Roche AG
Bristol-Myers Squibb Company
Teva Pharmaceuticals Industries Ltd.
Eli Lilly and Company
Novartis AG
Sanofi
Fresenius Kabi AG
Mylan N.V.
Kyowa Hakko Kirin Co Ltd.
Intercept Pharmaceuticals, Inc.
Accord Healthcare Inc.
Delcath Systems Inc.
Celgene Corporation
Johnson & Johnson
Starting With The New Decade On A Diligent Note In The Bile Duct Cancer Treatment Market? https://www.persistencemarketresearch.com/methodology/10094
Persistence Market Research’s new study on the global bile duct cancer treatment market reveals that by the end of 2025, APAC region will procure a global revenue share of over 45%.
In 2017, the global market for bile duct cancer treatments is anticipated to bring in revenues worth a little over US$ 168 Mn. Apart from rising incidence of bile duct cancer across the APAC and Middle East & Africa region, increasing healthcare spending is also expected to drive the demand for bile duct cancer treatments.
Towards the end of 2025, the global bile duct cancer treatment market is projected to soar at a robust CAGR of 8%, raking in revenues worth US$ 312.3 Mn.
Bile Duct Cancer Treatment – Key Challenges
The study has observed following factors as key hurdles hindering the overall expansion of global Cholangiocarcinoma treatment market:
high costs of cancer treatment in the US
lack of awareness on causes of Cholangiocarcinoma in developing regions
regulatory agencies rebuffing approval of expensive drugs
unavailability of effective cancer care in APAC region
poor diagnosis rate and absence of clinical data
The study also reveals that ongoing trials for development of drugs on bile duct cancer treatment are creating newer pathways for improving the efficiency of treatment. Companies are exploring the clinical benefits of fusing new chemical entities in existing drugs on treatment of bile duct cancer.
How About Obtaining Insights About The Region To Enter Concerning The Bile Duct Cancer Treatment Market? Press The “Purchase Now” Button To Have Our Bile Duct Cancer Treatment Market Report! https://www.persistencemarketresearch.com/checkout/10094
The key players in global bile duct cancer treatment market are also seeking regulatory approval of combination therapies for treatment of Cholangiocarcinoma.
Key Excerpts from the Study
Treatment of bile duct cancer is presently achieved through combination therapies associated with chemotherapy. The study anticipates that by the end of forecast period, close to 70% of global bile duct cancer treatment revenues will be accounted by the Gemicitabine Combination Therapy.
In 2017 and beyond, more than 85% of global market value will be attributed by extrahepatic Cholangiocarcinoma as a disease indicator.
The study also observes hospital pharmacies as largest distribution channel for bile duct cancer drugs, revenues from which are expected to reach nearly US$ 250 Mn by 2025-end.
The global market for Cholangiocarcinoma treatment is also witnessing dominance from external beam radiation therapy as these services are pegged to procure more than half of market’s value through 2025.
About Us :-
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.
Contact us:
Persistence Market Research Address – 305 Broadway, 7th FloorNew York City, NY 10007 United States U.S. Ph. – +1-646-568-7751 USA-Canada Toll-free – +1 800-961-0353 Sales – [email protected] Website – https://www.persistencemarketresearch.com
0 notes
Text
Global Liver Cancer Treatment MarketSize, Share, Development and Forecast Overview forecast year 2020
A new market study, titled “Global Liver Cancer Treatment Market Research and Forecast, 2018-2023” has been featured on WiseG…
October 05, 2020
Liver cancer, also referred to as hepatic cancer is a disease that destructs normal cells in the liver and is caused due to hepatitis C and hepatitis B or alcohol consumption. Malignant or cancerous cells that develop in the normal cells of the liver are called hepatocellular carcinoma and the one that arises in the ducts of the liver is called cholangiocarcinoma. The increasing prevalence of liver cancer across the globe and the approval of multiple liver cancer drugs are estimated to be the major factors that are driving the growth of the market. In addition, supporting government initiatives, drug development with regards to cancer and increasing health expenditure is also estimated to be the major factors that are driving the growth of the market.
Over the past few years, the increased prevalence of liver cancer has been witnessed. According to the American Cancer Society, about 42,220 new cases, 30,610 in men and 11,610 in women were diagnosed in 2018 in the US. It was estimated that about 30,200 people, nearly 20,540 men, and 9,660 women will die due to liver cancer in 2018. Since 1980, liver cancer incidence has more than tripled, however, the rates in young adults have begun to decline. The prevalence of liver cancer is seen more often in men than in women. Due to the increasing prevalence of liver cancer, the demand for treatment of liver cancer will increases. As a result, the global liver cancer treatment market is expected to witness growth in the near future.
However, there are certain factors that are hampering the growth of the market. The complex clinical trials process and high treatment costs are estimated to be the major constraints in the growth of the market. Besides these restraints, growing health awareness and new research and development are estimated to develop myriad growth opportunities for the growth of the market in the near future.
The global liver cancer treatment market is further studied on the basis of the geographical regions that are contributing significantly towards the growth of the market. North America region is estimated to account for a major share in the global liver cancer treatment market owing to the increasing prevalence of liver cancer due to risk factors such as Hepatitis C virus infection and alcoholic liver disease in the region. Additionally, high adoption of innovative technology, established infrastructure for research and development and presence of key pharmaceutical companies are the major factors for growth of liver cancer market in the region. Asia-Pacific is estimated to be the fastest growing market during the forecast period. The growth is observed in the region owing to the growing aged population and increasing health expenditure in the emerging economies such as India and China.
Key players of the global liver cancer treatment market are market are 4SC AG, Alnylam Pharmaceuticals, Inc., ArQule Inc., Aveo Pharmaceuticals, Inc., Bayer AG, Bristol-Myers Squibb Co., and so on. In order to stay competitive in the market, these key players adopt strategies such as product launch, merger & acquisitions, FDA approval, geographical expansion and so forth.
Research methodology
ALSO READ : https://icrowdnewswire.com/2019/10/17/liver-cancer-treatment-market-major-manufacturers-trends-demand-share-analysis-to-2023/
The market study of the global liver cancer treatment market is incorporated by extensive primary and secondary research conducted by a research team at OMR. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The OMR team collects facts and data related to the market from different geographies to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. The numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analysts to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts to get first-hand information. Primary research brings authenticity to our reports.
Secondary sources include
• Financial reports of companies involved in the market
• Whitepapers, research-papers and news blogs
• Company websites and their product catalog
The report is intended for healthcare providers, research laboratories and government organization for overall market analysis and competitive analysis. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.
The report covers
• Comprehensive research methodology of the global liver cancer treatment market.
• In-depth analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the global liver cancer treatment market.
• Insights about market determinants which are stimulating the global liver cancer treatment market.
• Detailed and extensive market segments with regional distribution of researched revenues.
• Extensive profiles and recent developments of market players.
Companies Mentioned
1. 4SC AG
2. Alnylam Pharmaceuticals, Inc.
3. ArQule, Inc.
4. Aveo Pharmaceuticals, Inc.
5. Bayer AG
6. Becton and Dickinson, Co.
7. Bristol-Myers Squibb, Co.
8. Celsion Corp.
9. Dicerna Pharmaceuticals, Inc.
10. Eli Lilly and Co.
11. Exelixis, Inc.
12. F. Hoffmann-La Roche, Ltd.
13. FibroGen, Inc.
14. General Electric Co.
15. Merck KGaA
16. Novartis International AG
17. Nymox Pharmaceutical Corp.
18. Pfizer, Inc.
19. SMC Laboratories, Inc.
20. Thermo Fisher Scientific, Inc.
FOR MORE DETAILS : https://www.wiseguyreports.com/reports/3739570-global-liver-cancer-treatment-market-research-and-forecast-2018-2023
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Contact Us:
NORAH TRENT
Ph: +162-825-80070 (US)
Ph: +44 203 500 2763 (UK)
0 notes
Link
0 notes